Business Context and Reporting Period
Company: ORIC Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 18, 2025
Reporting Period: Fourth quarter and full year ended December 31, 2024.
Context: The filing serves to announce the issuance of a press release containing financial results for the specified period. The company is an emerging growth company listed on The Nasdaq Global Select Market under the symbol ORIC.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K and does not contain specific financial data points. The actual figures for revenue, profit, cash flow, margins, debt, and liquidity are located in the attached press release (Exhibit 99.1), which is incorporated by reference but not included in the input text. Therefore, the filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes versus the prior comparable period are detailed in the provided text. The document only confirms the announcement of results for the fourth quarter and full year ended December 31, 2024.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release issued on February 18, 2025, which contains the results and likely includes management commentary, but the content of that commentary is not present in the input text.
Risks and Contingencies: No specific risks, contingencies, or unusual items are described in the provided text.
Legal Disclaimer: The filing explicitly states that information furnished in Item 2.02 and Item 9.01 (including the press release) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 18, 2025) for actual revenue, net income, and cash flow figures.
- Verify the specific details of the fourth quarter and full-year 2024 performance against prior periods.
- Check for any forward-looking statements or guidance included in the attached press release.
- Confirm the company's status as an emerging growth company and any related accounting election implications.